-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...
-
Product Insights
Alzheimer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020
Alzheimer Diagnostic Tests are test that detects the disease before it causes the symptoms. It measures key proteins or protein patterns in blood or spinal fluid (biomarkers). GlobalData's Medical Devices sector report, “Alzheimer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Alzheimer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Alzheimer Diagnostic Tests Pipeline Assessment report provides key information...
-
Sector Analysis
Alzheimer’s Disease (AD): Competitive Landscape to 2026
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The degeneration of neurons starts in the brainstem before progressing to the hippocampus, frontal lobe, amygdala, parietal lobe, and temporal lobe. The cause of AD is unknown, but it appears to be multifactorial, with most research aimed at the Aβ peptides and tau proteins. The irregular clearance and metabolism of these proteins are likely contributors to the presentation of the disease....
-
Product Insights
Pick Disease Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Pick Disease Global Clinical Trials Review, H1, 2018" provides an overview of Pick Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Pick Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by impaired memory and thinking (known as dementia), and functional decline. With a rapidly accelerating worldwide prevalence, there is a growing societal pressure for curative treatment for AD patients. The burden of AD encompasses clinical burden to patients as well as economic burden to payers and patients and caregiver burden, adding to the urgent need for improved AD therapy. Significant efforts are being made to develop a new treatment...
-
Product Insights
Aphasia Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Aphasia Global Clinical Trials Review, H2, 2018" provides an overview of Aphasia clinical trials scenario. This report provides top line data relating to the clinical trials on Aphasia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Progressive Supranuclear Palsy Global Clinical Trials Review, H1, 2018" provides an overview of Progressive Supranuclear Palsy clinical trials scenario. This report provides top line data relating to the clinical trials on Progressive Supranuclear Palsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...